Logo image of CTMX

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

USA - NASDAQ:CTMX - US23284F1057 - Common Stock

3.2 USD
-0.08 (-2.44%)
Last: 10/17/2025, 8:04:33 PM
3.24 USD
+0.04 (+1.25%)
After Hours: 10/17/2025, 8:04:33 PM
Fundamental Rating

5

Taking everything into account, CTMX scores 5 out of 10 in our fundamental rating. CTMX was compared to 536 industry peers in the Biotechnology industry. While CTMX has a great health rating, its profitability is only average at the moment. CTMX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

CTMX had positive earnings in the past year.
In the past year CTMX has reported a negative cash flow from operations.
In the past 5 years CTMX reported 4 times negative net income.
In the past 5 years CTMX reported 4 times negative operating cash flow.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of CTMX (27.41%) is better than 97.95% of its industry peers.
Looking at the Return On Equity, with a value of 40.02%, CTMX belongs to the top of the industry, outperforming 98.13% of the companies in the same industry.
CTMX has a Return On Invested Capital of 25.08%. This is amongst the best in the industry. CTMX outperforms 98.13% of its industry peers.
Industry RankSector Rank
ROA 27.41%
ROE 40.02%
ROIC 25.08%
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

1.3 Margins

Looking at the Profit Margin, with a value of 34.01%, CTMX belongs to the top of the industry, outperforming 96.64% of the companies in the same industry.
CTMX's Operating Margin of 30.56% is amongst the best of the industry. CTMX outperforms 96.83% of its industry peers.
Industry RankSector Rank
OM 30.56%
PM (TTM) 34.01%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

More info and screens

8

2. Health

2.1 Basic Checks

CTMX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CTMX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CTMX has more shares outstanding
CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CTMX has an Altman-Z score of 3.02. This indicates that CTMX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.02, CTMX is in the better half of the industry, outperforming 69.22% of the companies in the same industry.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.02
ROIC/WACC2.68
WACC9.35%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.20 indicates that CTMX has no problem at all paying its short term obligations.
CTMX has a Current ratio (4.20) which is comparable to the rest of the industry.
CTMX has a Quick Ratio of 4.20. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.20, CTMX is in line with its industry, outperforming 49.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 4.2
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 306.43%, which is quite impressive.
The Revenue has grown by 18.01% in the past year. This is quite good.
The Revenue has been growing by 19.15% on average over the past years. This is quite good.
EPS 1Y (TTM)306.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.75%
Revenue 1Y (TTM)18.01%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-25.71%

3.2 Future

CTMX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -51.75% yearly.
Based on estimates for the next years, CTMX will show a decrease in Revenue. The Revenue will decrease by -0.20% on average per year.
EPS Next Y-91.46%
EPS Next 2Y-67.9%
EPS Next 3Y-45.06%
EPS Next 5Y-51.75%
Revenue Next Year-23.36%
Revenue Next 2Y-40.29%
Revenue Next 3Y-33.54%
Revenue Next 5Y-0.2%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 5.61, the valuation of CTMX can be described as very cheap.
97.95% of the companies in the same industry are more expensive than CTMX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.40. CTMX is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.61
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CTMX is valued cheaply inside the industry as 97.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.12
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

A cheap valuation may be justified as CTMX's earnings are expected to decrease with -45.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.9%
EPS Next 3Y-45.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (10/17/2025, 8:04:33 PM)

After market: 3.24 +0.04 (+1.25%)

3.2

-0.08 (-2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners78.75%
Inst Owner Change0.01%
Ins Owners0.6%
Ins Owner Change3.95%
Market Cap527.71M
Analysts84.29
Price Target5.9 (84.38%)
Short Float %19.93%
Short Ratio8.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.1%
Min EPS beat(2)98.72%
Max EPS beat(2)113.47%
EPS beat(4)4
Avg EPS beat(4)141.82%
Min EPS beat(4)98.72%
Max EPS beat(4)215.22%
EPS beat(8)8
Avg EPS beat(8)146.11%
EPS beat(12)10
Avg EPS beat(12)101.81%
EPS beat(16)11
Avg EPS beat(16)73.27%
Revenue beat(2)2
Avg Revenue beat(2)42.82%
Min Revenue beat(2)23.76%
Max Revenue beat(2)61.87%
Revenue beat(4)4
Avg Revenue beat(4)66.28%
Min Revenue beat(4)23.76%
Max Revenue beat(4)92.34%
Revenue beat(8)8
Avg Revenue beat(8)60.6%
Revenue beat(12)10
Avg Revenue beat(12)36.87%
Revenue beat(16)10
Avg Revenue beat(16)12.56%
PT rev (1m)0.62%
PT rev (3m)5.19%
EPS NQ rev (1m)-5.79%
EPS NQ rev (3m)39.73%
EPS NY rev (1m)89.94%
EPS NY rev (3m)115.37%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-1.06%
Revenue NY rev (1m)-0.79%
Revenue NY rev (3m)18.22%
Valuation
Industry RankSector Rank
PE 5.61
Fwd PE N/A
P/S 3.74
P/FCF N/A
P/OCF N/A
P/B 4.4
P/tB 4.46
EV/EBITDA 6.12
EPS(TTM)0.57
EY17.81%
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.86
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.41%
ROE 40.02%
ROCE 31.75%
ROIC 25.08%
ROICexc N/A
ROICexgc N/A
OM 30.56%
PM (TTM) 34.01%
GM N/A
FCFM N/A
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 15.57%
Cap/Sales 0.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 4.2
Altman-Z 3.02
F-Score6
WACC9.35%
ROIC/WACC2.68
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)306.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.75%
EPS Next Y-91.46%
EPS Next 2Y-67.9%
EPS Next 3Y-45.06%
EPS Next 5Y-51.75%
Revenue 1Y (TTM)18.01%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-25.71%
Revenue Next Year-23.36%
Revenue Next 2Y-40.29%
Revenue Next 3Y-33.54%
Revenue Next 5Y-0.2%
EBIT growth 1Y654.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year309.72%
EBIT Next 3Y-10.1%
EBIT Next 5YN/A
FCF growth 1Y-48.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.83%
OCF growth 3YN/A
OCF growth 5YN/A